The impact of COVID-19 is wide-reaching with disruptions to supply chains likely to continue over the coming years. In this article, Dave Elder discusses the effect of the pandemic on the supply and demand of critical medicines and what this means for pharma supply chains.
List view / Grid view
Filter the results
WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
A clinical trial to test the protective efficacy of hydroxychloroquine against COVID-19 has found it was as effective as the placebo used in the trial.
New findings have revealed that over 2,000 clinical trials are being conducted to test COVID-19 therapies while 583 companies are involved in treatment and vaccine development.
After evidence suggesting hydroxychloroquine has no benefit against COVID-19, the MHRA has suspended further recruitment to clinical trials investigating the drug in the UK.
FDA revokes emergency use authorisation for chloroquine and hydroxychloroquine as COVID-19 treatments
Following ongoing analysis and emerging scientific data, the FDA has taken away its emergency use authorisation for chloroquine and hydroxychloroquine, finding they are unlikely to be effective as COVID-19 treatments.
The RECOVERY trial has stopped enrolment for the hydroxychloroquine arm after data revealed the drug had no meaningful benefit for hospitalised COVID-19 patients.
The WHO has paused the hydroxychloroquine arm of a global trial while it investigates safety concerns highlighted by published studies.
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
The COVID-19 European Medicines Agency (EMA) pandemic Task Force (COVID-ETF) warned that chloroquine and hydroxychloroquine are yet to be proved effective at treating COVID-19 and that their side effects could be fatal.
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.
An open letter from doctors highlights that although chloroquine and hydroxychloroquine are strong candidates to fight COVID-19, there is a limited supply.
The enterprise announced it will donate two million hydroxychloroquine tablets and the same of matched placebo to the multi-national COPCOV study.